NCT02759042

Brief Summary

The primary objective is to provide continued access to PRO 140 to a subject who has completed participation in PRO140\_CD02.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2016

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 3, 2016

Completed
Last Updated

March 13, 2018

Status Verified

August 1, 2017

First QC Date

April 19, 2016

Last Update Submit

March 12, 2018

Conditions

HIV

Interventions

PRO 140DRUG

PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Also known as: PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5

Eligibility Criteria

Age55 Years - 56 Years
Sexmale
Age GroupsAdult (18-64)
This study will recruit one treatment-experienced, HIV-1 infected patient with CCR5-tropic virus, who has participated in PRO 140\_CD02 clinical trial and is continuing to derive clinical benefit from PRO 140 treatment.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

CD02 EA Investigational site

Orlando, Florida, 32803, United States

Location

MeSH Terms

Interventions

leronlimab

Study Officials

  • Edwin DeJesus, MD, FIDSA

    Orlando Immunology Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 19, 2016

First Posted

May 3, 2016

Last Updated

March 13, 2018

Record last verified: 2017-08

Locations

US(1)